These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 18676986)

  • 1. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
    Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
    Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
    Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
    Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.
    Stohl W; Metyas S; Tan SM; Cheema GS; Oamar B; Xu D; Roschke V; Wu Y; Baker KP; Hilbert DM
    Arthritis Rheum; 2003 Dec; 48(12):3475-86. PubMed ID: 14673998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.
    Cheema GS; Roschke V; Hilbert DM; Stohl W
    Arthritis Rheum; 2001 Jun; 44(6):1313-9. PubMed ID: 11407690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raised serum APRIL levels in patients with systemic lupus erythematosus.
    Koyama T; Tsukamoto H; Miyagi Y; Himeji D; Otsuka J; Miyagawa H; Harada M; Horiuchi T
    Ann Rheum Dis; 2005 Jul; 64(7):1065-7. PubMed ID: 15576416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
    Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
    Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients.
    Hong SD; Reiff A; Yang HT; Migone TS; Ward CD; Marzan K; Shaham B; Phei WC; Garza J; Bernstein B; Stohl W
    Arthritis Rheum; 2009 Nov; 60(11):3400-9. PubMed ID: 19877053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices.
    Hegazy M; Darwish H; Darweesh H; El-Shehaby A; Emad Y
    Clin Immunol; 2010 Apr; 135(1):118-24. PubMed ID: 20116334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus.
    Stohl W; Metyas S; Tan SM; Cheema GS; Oamar B; Roschke V; Wu Y; Baker KP; Hilbert DM
    Ann Rheum Dis; 2004 Sep; 63(9):1096-103. PubMed ID: 15308519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus.
    Ju S; Zhang D; Wang Y; Ni H; Kong X; Zhong R
    Clin Biochem; 2006 Dec; 39(12):1131-7. PubMed ID: 17069785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus.
    Vincent FB; Northcott M; Hoi A; Mackay F; Morand EF
    Lupus; 2013 Aug; 22(9):873-84. PubMed ID: 23846230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
    Toubi E; Kessel A; Rosner I; Rozenbaum M; Paran D; Shoenfeld Y
    Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BLyS and April serum levels in patients with autoimmune thyroid diseases.
    Fabris M; Grimaldi F; Villalta D; Picierno A; Fabro C; Bolzan M; De Vita S; Tonutti E
    Autoimmun Rev; 2010 Jan; 9(3):165-9. PubMed ID: 19647102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum levels of APRIL, but not BAFF, in patients with atopic dermatitis.
    Matsushita T; Fujimoto M; Echigo T; Matsushita Y; Shimada Y; Hasegawa M; Takehara K; Sato S
    Exp Dermatol; 2008 Mar; 17(3):197-202. PubMed ID: 17979975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF.
    Matsushita T; Fujimoto M; Hasegawa M; Tanaka C; Kumada S; Ogawa F; Takehara K; Sato S
    J Rheumatol; 2007 Oct; 34(10):2056-62. PubMed ID: 17896803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.
    Zandman-Goddard G; Blank M; Langevitz P; Slutsky L; Pras M; Levy Y; Shovman O; Witte T; Doria A; Rovensky J; Shoenfeld Y
    Ann Rheum Dis; 2005 Dec; 64(12):1698-702. PubMed ID: 16014675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression and significance of BLyS/April in patients with acute idiopathic thrombocytopenic purpura].
    Wang GB; Li CR; Li CG; Wang Y; Yang J
    Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):595-8. PubMed ID: 19175985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-lymphocyte stimulator and a proliferation-inducing ligand serum levels in IgA-deficient patients with and without celiac disease.
    Fabris M; De Vita S; Visentini D; Fabro C; Picierno A; Lerussi A; Villalta D; Alessio MG; Tampoia M; Tonutti E
    Ann N Y Acad Sci; 2009 Sep; 1173():268-73. PubMed ID: 19758161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies.
    Krystufková O; Vallerskog T; Helmers SB; Mann H; Putová I; Belácek J; Malmström V; Trollmo C; Vencovsky J; Lundberg IE
    Ann Rheum Dis; 2009 Jun; 68(6):836-43. PubMed ID: 18628284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.